Introduction: A Paradigm Shift in Oncology
For decades, the standard for cancer detection—and the subsequent monitoring of its recurrence—has been dominated by physical imaging, such as CT scans, MRIs, and PET scans. While these technologies have saved countless lives, they are inherently reactive; by the time a tumor is visible on a scan, it has often already reached a size that is difficult to treat.
On October 26, 2026, the landscape of oncology underwent a profound transformation with the commercial launch of the Oncodetect molecular residual disease (MRD) test by Abbott. This next-generation diagnostic tool, built upon the pioneering "MAESTRO" technology developed at the Broad Institute of MIT and Harvard, represents a leap forward in the quest to identify cancer when it is still at the microscopic level. By analyzing circulating tumor DNA (ctDNA) in the bloodstream, this test provides clinicians with an unprecedented window into a patient’s post-treatment status, allowing for the potential of early intervention before a clinical relapse becomes apparent.
The Genesis of an Idea: From Graduate Research to Clinical Reality
The story of Oncodetect begins more than a decade ago with Viktor Adalsteinsson, a scientist whose career has been defined by the pursuit of more sensitive, non-invasive diagnostic tools. As a graduate student at the Massachusetts Institute of Technology (MIT), working within the lab of Chris Love, Adalsteinsson began exploring the potential of comprehensive sequencing for single circulating tumor cells.
Chronology of Innovation
- 2015: Adalsteinsson earns his PhD in chemical engineering, marking the transition from theoretical research to the establishment of his own laboratory at the Broad Institute.
- 2016–2022: The Adalsteinsson lab embarks on a rigorous period of analysis, studying thousands of liquid biopsy samples to understand how metastatic cancers evolve and evade standard therapies.
- 2023: Recognizing the clinical potential of their research, the Broad Institute enters a strategic research collaboration and licensing agreement with Exact Sciences (later acquired by Abbott in 2026).
- 2026: Following years of rigorous validation, Abbott launches the upgraded Oncodetect platform, utilizing the MAESTRO (Minor Allele Enriched Sequencing through Recognition Oligonucleotides) framework.
The core challenge Adalsteinsson set out to solve was the "needle in a haystack" problem. Blood contains a vast amount of healthy, cell-free DNA. Detecting the infinitesimal traces of DNA shed by a tumor—the molecular markers of residual disease—requires a level of sensitivity that traditional sequencing simply could not provide.
The Science of MAESTRO: Pushing Technical Boundaries
At the heart of the new Oncodetect test lies the MAESTRO technology. While the first-generation version of Oncodetect could track up to 200 mutations, the new iteration, powered by MAESTRO, represents a massive expansion in scope and precision.
Technical Capabilities
- Whole-Genome Coverage: Unlike previous iterations that focused on a limited set of genes, the new system scans across the whole genome to monitor up to 5,000 patient-specific cancer mutations.
- Unprecedented Sensitivity: The system is capable of detecting circulating tumor DNA levels at concentrations below 1 part per million—an achievement that requires extreme technical rigor and sophisticated algorithmic correction.
- Molecular Residual Disease (MRD) Detection: The primary goal of the test is to identify the presence of cancer cells that persist in the body after surgery or chemotherapy, even when those cells are undetectable by current imaging standards.
By tracking such a large number of mutations, the test essentially creates a "molecular fingerprint" of an individual’s specific tumor. This allows the test to be highly personalized, reducing the likelihood of false positives and increasing the confidence with which a physician can make treatment decisions.
Strategic Partnerships: Bridging the "Valley of Death"
In the medical research world, many promising technologies fail to reach patients—a phenomenon often referred to as the "valley of death" between laboratory discovery and commercial availability. The success of Oncodetect serves as a blueprint for how academic institutions and private industry can collaborate to bridge this gap.
Todd Golub, director of the Broad Institute, emphasizes that the success of the project was predicated on the unique ecosystem of the Broad, which fosters collaboration between genomic scientists, clinical oncologists at institutions like the Dana-Farber Cancer Institute, and industry partners.
"When we started the Broad, the idea from the very beginning was that our genomics research would benefit patients," said Golub. "It’s easy to say that, but it’s a long and arduous road. Viktor had the scientific ideas to solve the problem of sensitivity versus specificity, and the collaborative nature of our community helped bring it to the finish line."
The partnership with Abbott was essential. By integrating the Broad’s research into a scalable, clinically validated commercial product, the team ensured that the technology could meet the high regulatory and manufacturing standards required for patient care.
Official Responses and Clinical Implications
The launch of the test has been met with significant enthusiasm from both the research and medical communities. For the patient, the implications of Oncodetect are life-altering. By identifying residual disease early, clinicians can potentially adjust therapeutic regimens—such as escalating the dose of adjuvant therapy or introducing new, targeted treatments—before the cancer develops clinical symptoms.
Perspectives from Leadership
"I always knew that I wanted to pursue approaches that could improve the lives of cancer patients," says Viktor Adalsteinsson, now the senior director of the Gerstner Center for Cancer Diagnostics. "MAESTRO pushes the limits for molecular residual disease detection. We are thrilled to see that this technology will reach patients to inform more precise care."
Jorge Garces, divisional vice president of R&D at Abbott, echoes this sentiment: "The promise of innovation is ultimately measured by what it can mean for patients. Working with the Broad, we were able to take an extraordinary scientific innovation in MAESTRO and translate it into a test designed to give physicians more information about what may remain during and after cancer treatment."
The Gerstner Family Foundation, which has provided long-term support for the Broad’s cancer diagnostics research, views this launch as a validation of their mission. Elizabeth Gerstner, chair of the Foundation, noted that the launch demonstrates the power of "translating discoveries into better care for patients."
The Road Ahead: Future Directions in Diagnostics
Even as Oncodetect enters clinical use, the work at the Broad Institute’s Gerstner Center for Cancer Diagnostics continues at a rapid pace. Adalsteinsson and his team are already looking toward the next generation of liquid biopsy enhancements.
Emerging Technologies
- Priming Agents: One of the most ambitious projects currently underway involves the development of "priming agents." These are diagnostic drugs designed to be injected into a patient to slow the clearance of tumor DNA from the bloodstream. By increasing the amount of circulating DNA available, these agents could theoretically make liquid biopsy tests orders of magnitude more sensitive.
- Advanced Sequencing Methods: Beyond MAESTRO, the team has developed novel methods such as CODEC and Methyl CODEC. These techniques are designed to further enhance the accuracy of DNA sequencing, potentially allowing for the detection of rare genetic mutations that were previously invisible to modern science.
These ongoing efforts suggest that the launch of Oncodetect is not the end of the journey, but rather the establishment of a new foundation. As liquid biopsy technology matures, the ability to monitor cancer like a chronic condition—rather than a series of acute crises—is becoming an increasingly tangible reality.
Conclusion: A Validation of Multidisciplinary Science
The development and launch of the next-generation Oncodetect test serve as a powerful case study in the efficacy of the modern research university model. It highlights that when basic science is paired with a clear clinical objective, supported by long-term funding, and executed through strategic commercial partnerships, the impact on human health can be profound.
As cancer care moves toward a model defined by precision, early detection, and real-time monitoring, the work of Adalsteinsson, the Broad Institute, and Abbott provides a glimpse into a future where cancer recurrence is caught early enough to be effectively managed or even eradicated. For the thousands of patients who will undergo these tests in the coming years, this innovation represents more than just a diagnostic tool—it represents the hope of more time, more treatment options, and ultimately, better survival outcomes.
The Oncodetect test is a trademark of the Abbott group of companies.
About the Author
